Psoriatic arthritis management update - biotherapeutic options.
Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy (SpA) occurring in up to 30% of patients with psoriasis. It has a wide variation of annual incidence (median 6.4, range 0.1-3.1 per 10(5) people), based on analysis of 13 incidence and prevalence reviews published between 1987 and December 2006. Conventional treatments with antiinflammatory and disease modifying or antirheumatic drugs are not efficacious in all patients, in particular those with axial disease. This review examines new pharmacological developments in the treatment of PsA with a focus on biologic therapies.
Saber
Tajvur P
TP
Centre for Arthritis Research and Education, Dublin Academic Health Care, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
Veale
Douglas J
DJ
D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001685:Biological Factors / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D001685:Biological Factors; D014409:Tumor Necrosis Factor-alpha